COMMUNIQUÉS West-GlobeNewswire

Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders
25/08/2026
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential GROTON, Conn., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc. , a [...]
Trading in GN Store Nord shares by board members, executives and associated persons
25/08/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
25/08/2026
Recognition highlights Truvaga’s combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience ROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- [...]
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
25/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today [...]
4DMT to Participate in Upcoming Investor Conferences
25/08/2026
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
25/08/2026
Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome [...]
Nu-Tek BioSciences participera au salon BPI East 2026 à Boston pour établir des liens entre ses nutriments pour milieux de culture sans composants d’origine animale et les stratégies de croissance de ses clients du secteur pharmaceutique
25/08/2026
Nu-Tek rencontrera des dirigeants de l’industrie pharmaceutique lors du salon BioProcess International East, du 22 au 25 septembre à Boston, afin de discuter de peptones et d’hydrolysats de protéines 100 % sans [...]
Nu-Tek BioSciences to Attend BPI East 2026 in Boston, Connecting Animal-Free Culture Media Nutrients with Pharma Customer Growth Strategies
25/08/2026
Nu-Tek will meet with pharmaceutical leadership during BioProcess International East Sept. 22-25 in Boston to discuss 100% animal-origin-free peptones and protein hydrolysates, with a focus on product quality and supply [...]
Mixie Technologies, Inc. (OTC: MIXE) Portfolio Company HoloTwin Unveils TwinRuntime: Enterprise Digital Twins That Run in a Standard Web Browser, No Downloads Required
25/08/2026
Mixie Technologies' flagship portfolio company milestone caps a year that took HoloTwin from a strategic investment, to a CES 2026 award, to HoloTwin 2.0, and now to a browser-native runtime that puts living digital [...]
CVRx Responds to Letter from Pointillist Family Office
25/08/2026
MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
25/08/2026
TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic [...]
Annovis to Host Corporate Update Webinar on September 2, 2026
25/08/2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
25/08/2026
Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
25/08/2026
Presentation addressed potential applications in prolonged field care and military wound management settings WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or [...]
Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease
25/08/2026
Heidelberg, Germany, August 25, 2026 – Revier Therapeutics (“Revier” or “the Company”), today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the [...]
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
25/08/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”), today announced that it has entered into a SAFE note with Pep'd Inc. (“ Pep'd [...]
Transactions in connection with share buy-back program
25/08/2026
Company announcement no. 32 - 26 25 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Trading by management and close relations of management
25/08/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
25/08/2026
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4- [...]

Pages